Gene Therapy: Lyfgenia Voucher Denial Puts Sickle Cell Treatment At Risk, Bluebird Bio Says
The company said its financial viability is in jeopardy, along with patient access to Lyfgenia, if US FDA Commissioner Robert Califf does not reverse the denial of a rare pediatric disease priority review voucher.
